References
- Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Sem Reprod Endocrinol 1997; 15: 111–22
- Gollick H, Schramm M. Topical drug treatment in acne. Dermatology 1998; 196: 119–25
- Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol 1998; 39(Suppl): S38–44
- Quigley JW, Bucks DAW. Reduced skin irritation with tretinoin containing polyolprepolymer-2, a new topical tretinoin delivery system: a summary of preclinical and clinical investigations. J Am Acad Dermatol 1998; 38(Suppl): S5–10
- Lucky AW, Cullen SI, Funicella T, et al. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998; 38(Suppl): S24–30
- Lucky AW, Cullen SI, Jarratt MT, et al. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter, double-blind, parallel study. J Am Acad Dermatol 1998; 38(Suppl): S17–23
- Cunliffe WJ. A new topical retinoid—why a new topical acne therapy? Br J Dermatol 1998; 139(Suppl 52):1–2
- Weiss JS. Current options for the topical treatment of acne vulgaris. Pediat Dermatol 1997; 14(6): 480–8
- Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and US multicenter trials. J Am Acad Dermatol 1997; 36(Suppl): S126–34
- Gibson JR. Rationale for the development of new topical treatments for acne vulgaris. Cutis 1996; 57(1 Suppl): 13–9